Skip to main content

Advertisement

Table 2 Disease-specific summary of significant different biomarkers in cerebrospinal fluid

From: Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

ProteinControlsPDMSA
CCL280.6 ± 0.2b0.9 ± 0.2a0.8 ± 0.2
IL-88.4 ± 1.3bc7.6 ± 0.5a7.5 ± 0.4a
FGF-194.7 ± 0.8c4.2 ± 0.63.9 ± 0.7a
CD408.1 ± 0.5c7.6 ± 0.47.5 ± 0.4a
PD-L14.1 ± 0.6c3.7 ± 0.53.5 ± 0.4a
TGF-α6.0 ± 0.6c5.7 ± 0.45.5 ± 0.4a
SCF5.2 ± 0.7c4.8 ± 0.54.7 ± 0.3a
CSF-16.9 ± 0.5c6.5 ± 0.46.3 ± 0.2a
uPA6.0 ± 0.6c7.0 ± 0.56.8 ± 0.4a
VEGF-A9.6 ± 0.7c9.1 ± 0.68.9 ± 0.4a
CCL233.1 ± 1.0bc2.5 ± 0.5a2.5 ± 0.3a
CX3CL13.2 ± 0.6bc2.6 ± 0.5a2.4 ± 0.3a
MCP-25.0 ± 0.9bc4.2 ± 0.8a4.2 ± 0.5a
CXCL16.0 ± 1.2bc4.9 ± 0.5a4.9 ± 0.6a
DNER10.0 ± 0.2c9.9 ± 0.2c9.8 ± 0.1ab
β-NGF1.8 ± 0.5c1.5 ± 0.3c1.3 ± 0.2ab
  1. Data are expressed as normalized protein expression (NPX) values (mean ± standard deviation). Data were analyzed using rank analysis of covariance followed by ANOVA with Games Howell as a post hoc test. Only statistically significant (p < 0.05) differences are noted. aversus controls; bversus Parkinson’s disease (PD); cversus multiple system atrophy (MSA)